Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amin Rostami

Showing results (91-100 of 305) with videos related to

Pageof 31
Sort By:
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 20, 2014
Meta-analysis of the turnover of intestinal epithelia in preclinical animal species and humansAdam S Darwich, Umair Aslam, Darren M Ashcroft, et al.
Journal of Pharmaceutical Sciences|June 11, 2008
Metabolism of dextrorphan by CYP2D6 in different recombinantly expressed systems and its implications for the in vitro assessment of dextromethorphan metabolismLinh M Van, Sunil Sarda, Judith A Hargreaves, et al.
The AAPS Journal|July 2, 2016
Key to Opening Kidney for In Vitro-In Vivo Extrapolation Entrance in Health and Disease: Part I: In Vitro Systems and Physiological DataDaniel Scotcher, Christopher Jones, Maria Posada, et al.
Annual Review of Analytical Chemistry (Palo Alto, Calif.)|February 22, 2020
Mass Spectrometry of Human TransportersBrahim Achour, Zubida M Al-Majdoub, Amin Rostami-Hodjegan, et al.
The AAPS Journal|August 11, 2016
Key to Opening Kidney for In Vitro-In Vivo Extrapolation Entrance in Health and Disease: Part II: Mechanistic Models and In Vitro-In Vivo ExtrapolationDaniel Scotcher, Christopher Jones, Maria Posada, et al.
Frontiers in Pharmacology|April 12, 2018
Application of Physiologically Based Pharmacokinetic (PBPK) Modeling Within a Bayesian Framework to Identify Poor Metabolizers of Efavirenz (PM), Using a Test Dose of EfavirenzManoranjenni Chetty, Theresa Cain, Janak Wedagedera, et al.
Clinical Pharmacology and Therapeutics|May 15, 2022
Effect of Chronic Kidney Disease on the Renal Secretion via Organic Anion Transporters 1/3: Implications for Physiologically-Based Pharmacokinetic Modeling and Dose AdjustmentShawn Pei Feng Tan, Daniel Scotcher, Amin Rostami-Hodjegan, et al.
Clinical Pharmacokinetics|September 2, 2022
Altered Bioavailability and Pharmacokinetics in Crohn's Disease: Capturing Systems Parameters for PBPK to Assist with Predicting the Fate of Orally Administered DrugsSarah Alrubia, Jialin Mao, Yuan Chen, et al.
Journal of Clinical Pharmacology|May 16, 2025
Dextromethorphan versus Dextrorphan: A Quantitative Comparison of Antitussive Potency following Separate Administration of MetaboliteSaeed Rezaee, Caroline E Wright, Alyn H Morice, et al.
Journal of Clinical Pharmacology|November 17, 2004
Assessment of in vivo CYP2D6 activity: differential sensitivity of commonly used probes to urine pHMahmut Ozdemir, Kim H Crewe, Geoffrey T Tucker, et al.
Pageof 31

Showing results (91-100 of 305) with videos related to

Sort By:
Pageof 31
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 20, 2014
Meta-analysis of the turnover of intestinal epithelia in preclinical animal species and humansAdam S Darwich, Umair Aslam, Darren M Ashcroft, et al.
Journal of Pharmaceutical Sciences|June 11, 2008
Metabolism of dextrorphan by CYP2D6 in different recombinantly expressed systems and its implications for the in vitro assessment of dextromethorphan metabolismLinh M Van, Sunil Sarda, Judith A Hargreaves, et al.
The AAPS Journal|July 2, 2016
Key to Opening Kidney for In Vitro-In Vivo Extrapolation Entrance in Health and Disease: Part I: In Vitro Systems and Physiological DataDaniel Scotcher, Christopher Jones, Maria Posada, et al.
Annual Review of Analytical Chemistry (Palo Alto, Calif.)|February 22, 2020
Mass Spectrometry of Human TransportersBrahim Achour, Zubida M Al-Majdoub, Amin Rostami-Hodjegan, et al.
The AAPS Journal|August 11, 2016
Key to Opening Kidney for In Vitro-In Vivo Extrapolation Entrance in Health and Disease: Part II: Mechanistic Models and In Vitro-In Vivo ExtrapolationDaniel Scotcher, Christopher Jones, Maria Posada, et al.
Frontiers in Pharmacology|April 12, 2018
Application of Physiologically Based Pharmacokinetic (PBPK) Modeling Within a Bayesian Framework to Identify Poor Metabolizers of Efavirenz (PM), Using a Test Dose of EfavirenzManoranjenni Chetty, Theresa Cain, Janak Wedagedera, et al.
Clinical Pharmacology and Therapeutics|May 15, 2022
Effect of Chronic Kidney Disease on the Renal Secretion via Organic Anion Transporters 1/3: Implications for Physiologically-Based Pharmacokinetic Modeling and Dose AdjustmentShawn Pei Feng Tan, Daniel Scotcher, Amin Rostami-Hodjegan, et al.
Clinical Pharmacokinetics|September 2, 2022
Altered Bioavailability and Pharmacokinetics in Crohn's Disease: Capturing Systems Parameters for PBPK to Assist with Predicting the Fate of Orally Administered DrugsSarah Alrubia, Jialin Mao, Yuan Chen, et al.
Journal of Clinical Pharmacology|May 16, 2025
Dextromethorphan versus Dextrorphan: A Quantitative Comparison of Antitussive Potency following Separate Administration of MetaboliteSaeed Rezaee, Caroline E Wright, Alyn H Morice, et al.
Journal of Clinical Pharmacology|November 17, 2004
Assessment of in vivo CYP2D6 activity: differential sensitivity of commonly used probes to urine pHMahmut Ozdemir, Kim H Crewe, Geoffrey T Tucker, et al.
Pageof 31